| Identification | Back Directory | [Name]
3'-O-MOE-5Me-C(Bz)-2'-phosphoramidite | [CAS]
1098233-10-3 | [Synonyms]
3'-O-MOE-5Me-C(Bz)-2'-phosphoramidite
3’-O-MOE-5Me-C(Bz)-2’-phosphoramidite
N4-Bz-5’-O-DMTr-3’-O-(2-methoxyethyl)-5-methyl cytidine-2’-CED-phosphoramidite
Cytidine, N-benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-3'-O-(2-methoxyethyl)-5-methyl-, 2'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite]
N-[1-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-4-(2-methoxyethoxy)tetrahydrofuran-2-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide | [Molecular Formula]
C50H60N5O10P | [MDL Number]
MFCD31814036 | [MOL File]
1098233-10-3.mol | [Molecular Weight]
922.01 |
| Hazard Information | Back Directory | [Uses]
3’-O-MOE-5Me-C(Bz)-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | [References]
[1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
|
|